+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HIV Clinical Trials Market - Global Forecast 2026-2032- Product Image
HIV Clinical Trials Market - Global Forecast 2026-2032- Product Image
New

HIV Clinical Trials Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666075
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The HIV clinical trials market is experiencing accelerated transformation, shaped by scientific breakthroughs and shifting operational imperatives. As research advancements drive both complexity and opportunity, organizations now face heightened decisions that impact development strategies, supply chain resilience, and regulatory navigation.

Market Snapshot

The HIV Clinical Trials Market grew from USD 1.55 billion in 2025 to USD 2.16 billion in 2026. It is projected to expand at a CAGR of 41.45%, achieving a market value of USD 17.60 billion by 2032. This robust growth reflects surging innovation, evolving clinical research demands, and broader stakeholder engagement across the global healthcare landscape.

Scope & Segmentation

  • Drug Classes: Includes Entry Inhibitors (e.g., enfuvirtide, maraviroc), Integrase Strand Transfer Inhibitors (bictegravir, dolutegravir, elvitegravir, raltegravir), Non-Nucleoside Reverse Transcriptase Inhibitors (efavirenz, etravirine, nevirapine, rilpivirine), Nucleoside Reverse Transcriptase Inhibitors (emtricitabine, lamivudine, tenofovir, zidovudine), and Protease Inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir).
  • Trial Phases: Encompasses Phase I (first-in-human), Phase IIa/IIb (exploratory and confirmatory), Phase III (efficacy), and Phase IV (post-marketing).
  • End Users: Clinical research is conducted in clinics, hospitals, academic institutes, and contract research organizations.
  • Route of Administration: Covers oral, injectable, and transdermal therapies, influencing trial management and adherence approaches.
  • Distribution Pathways: Hospital pharmacies, online channels, and retail outlets (chain and independent); impact late-phase planning and patient accessibility.
  • Age Cohorts: Adult, geriatric, and pediatric populations inform safety, monitoring, and formulation requirements.
  • Geographic Regions: Americas, Europe Middle East & Africa, Asia-Pacific, each bringing distinct recruitment, regulatory, and operational dynamics.
  • Technological Innovations: Adaptive and decentralized clinical trial models, real-world evidence integration, and digital monitoring platforms.

Key Takeaways

  • Scientific advances, particularly in integrase and protease inhibitors, are redefining trial protocols and expanding focus on long-term regimen tolerability.
  • Operational complexity is heightened by hybrid and decentralized study designs, which broaden patient access but require new data integrity measures.
  • Strategic corporate behaviors now blend in-house virology with partnerships and licensing, optimizing trial reach and expediting development of next-generation compounds.
  • Regulatory frameworks are adapting, supporting streamlined review for therapies with high safety and biological plausibility, thereby incentivizing adaptive trial structures.
  • Regional variation—such as strong infrastructure in the Americas, harmonization challenges in EMEA, and expansion in Asia-Pacific—demands tailored recruitment and protocol strategies.
  • Community engagement and transparent data practices are becoming central to ethical recruitment, particularly for pediatric and geriatric cohorts, and to data harmonization efforts.

Tariff Impact

Tariff-driven trade measures are intensifying operational and budgetary pressures in HIV clinical research. Elevated costs and import lead-time uncertainties affect trial timelines, requiring careful supplier selection and local fill-and-finish arrangements. Sponsors must actively manage inventory, renegotiate contracts to clarify customs responsibilities, and consider alternative vendors to mitigate regional disparities in tariff exposure. These policy shifts necessitate contingency planning and integration of trade risk scenarios within broader trial execution frameworks.

Methodology & Data Sources

This report utilizes a mixed-methods approach, combining comprehensive secondary research from peer-reviewed literature, regulatory documents, and industry white papers with structured primary interviews among clinical operations, regulatory affairs, and supply chain professionals. Robust data triangulation ensures accuracy and operational relevance across findings.

Why This Report Matters

  • Enables leaders to quantify risk and resilience strategies for HIV clinical trials in the face of evolving supply chain and regulatory challenges.
  • Provides actionable segmentation and regional insights to fine-tune trial design, site selection, and partnership models aligned to emerging operational realities.
  • Supports forward-looking investment and access strategies with integrated analysis targeted to sponsor, CRO, and procurement stakeholders.

Conclusion

Successful navigation of the HIV clinical trials market now requires aligning innovation in drug therapy with resilient, adaptive operations and proactive regional strategies. This report offers a holistic foundation for informed decisions that strengthen resilience and drive impactful, patient-focused research outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. HIV Clinical Trials Market, by Drug Class
8.1. Entry Inhibitors
8.1.1. Enfuvirtide
8.1.2. Maraviroc
8.2. Integrase Strand Transfer Inhibitors
8.2.1. Bictegravir
8.2.2. Dolutegravir
8.2.3. Elvitegravir
8.2.4. Raltegravir
8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
8.3.1. Efavirenz
8.3.2. Etravirine
8.3.3. Nevirapine
8.3.4. Rilpivirine
8.4. Nucleoside Reverse Transcriptase Inhibitors
8.4.1. Emtricitabine
8.4.2. Lamivudine
8.4.3. Tenofovir
8.4.4. Zidovudine
8.5. Protease Inhibitors
8.5.1. Atazanavir
8.5.2. Darunavir
8.5.3. Fosamprenavir
8.5.4. Lopinavir
9. HIV Clinical Trials Market, by Trial Phase
9.1. Phase I
9.2. Phase II
9.2.1. Phase IIa
9.2.2. Phase IIb
9.3. Phase III
9.4. Phase IV
10. HIV Clinical Trials Market, by End User
10.1. Clinics
10.2. Hospitals
10.3. Research Institutes
10.3.1. Academic Institutes
10.3.2. Contract Research Organizations
11. HIV Clinical Trials Market, by Route Of Administration
11.1. Injectable
11.2. Oral
11.3. Transdermal
12. HIV Clinical Trials Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
12.3.1. Chain Pharmacies
12.3.2. Independent Pharmacies
13. HIV Clinical Trials Market, by Patient Age Group
13.1. Adult
13.2. Geriatric
13.3. Pediatric
14. HIV Clinical Trials Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. HIV Clinical Trials Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. HIV Clinical Trials Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States HIV Clinical Trials Market
18. China HIV Clinical Trials Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Gilead Sciences, Inc.
19.7. Johnson & Johnson
19.8. Merck & Co., Inc.
19.9. Moderna, Inc.
19.10. Pfizer Inc.
19.11. Roche Holding AG
19.12. Sanofi S.A.
19.13. Takeda Pharmaceutical Company Limited
19.14. ViiV Healthcare Limited
List of Figures
FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 166. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 214. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 216. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 218. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 220. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 221. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 223. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 226. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 232. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 233. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 234. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 235. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 236. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 242. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 244. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 245. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 246. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 247. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 248. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 249. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 250. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 251. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 253. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 255. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 256. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 263. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 264. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 265. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 266. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 268. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 269. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 270. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 271. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 272. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 273. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 275. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 276. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 277. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 278. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 279. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 280. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 281. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 282. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 283. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 284. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 285. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 286. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 287. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 288. GCC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 289. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 290. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 291. GCC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 292. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 293. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 294. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 295. GCC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 296. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 297. GCC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 298. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 299. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 300. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 301. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 302. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DI

Companies Mentioned

The key companies profiled in this HIV Clinical Trials market report include:
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.16 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.6 Billion
Compound Annual Growth Rate41.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

HIV Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

HIV Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2025 - Product Image

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2025

  • Report
  • 250 Pages
  • Global
From
HIV Clinical Trials - Global Strategic Business Report - Product Image

HIV Clinical Trials - Global Strategic Business Report

  • Report
  • 379 Pages
  • Global
From
Anti-Retroviral Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-Retroviral Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
HIV Drugs Market Size Analysis Report - Market Share, Forecast Trends and Outlook 2025-2034 - Product Image

HIV Drugs Market Size Analysis Report - Market Share, Forecast Trends and Outlook 2025-2034

  • Report
  • 350 Pages
  • Global
From

About the HIV Clinical Trial Market

The HIV Clinical Trial market is a subset of the larger Clinical Trials market, which focuses on the development of treatments and preventative measures for HIV/AIDS. HIV Clinical Trials are conducted to evaluate the safety and efficacy of new drugs, vaccines, and other treatments for HIV/AIDS. These trials are conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The HIV Clinical Trial market is highly regulated, with stringent requirements for the design, conduct, and reporting of clinical trials. The market is also subject to a variety of legal and ethical considerations, including patient privacy and informed consent. Companies in the HIV Clinical Trial market include Gilead Sciences, Merck, ViiV Healthcare, Janssen Pharmaceuticals, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.